Effects of methadone on QT-interval dispersion

Pharmacotherapy

Volumn 25, Issue 11 I, 2005, Pages 1523-1529

  Krantz, Mori J ^a   Lowery, Christopher M ^a   Martell, Bridget A ^b   Gourevitch, Marc N ^c   Arnsten, Julia H ^d  

^a DENVER HEALTH MEDICAL CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Methadone; QT dispersion; QT prolongation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; DIURETIC AGENT; EPHEDRA EXTRACT; ERYTHROMYCIN; METHADONE; MOXIFLOXACIN; PHENYTOIN; POTASSIUM CHANNEL HERG; QUINIDINE; SOTALOL; TERFENADINE; THIORIDAZINE;

ADULT; AGED; ARTICLE; COMORBIDITY; DRUG EFFECT; DRUG SELECTIVITY; ELECTROCARDIOGRAM; FEMALE; HEART ARRHYTHMIA; HEART CONDUCTION; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; QT DISPERSION; QT PROLONGATION;

ADULT; ANTI-ARRHYTHMIA AGENTS; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; METHADONE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 27644589582     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.11.1523     Document Type: Article

References (48)

1. Ballesteros MF, Budnitz DS, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in deaths due to methadone in North Carolina [letter]. JAMA 2003;290:40.
2. Sorg MH, Greenwald M, for the Maine Office of the Attorney General and the Maine Office of Substance Abuse. Maine drug-related mortality patterns: 1997-2002. Available from http://www.state.me.us/ag/pr/drugreport.pdf. Accessed August 6, 2004.
3. Walker PW, Klein D, Kasza L. High-dose methadone and ventricular arrhythmias: a report of three cases. Pain 2003;103:321-4.
4. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 2002;137:501-4.
5. Gil M, Sala M, Anguera I, et al. QT prolongation and torsade de pointes in patients infected with human immunodeficiency virus and treated with methadone. Am J Cardiol 2003;92:995-7.
6. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of oral methadone on cardiac repolarization and conduction in opioid users. Am J Cardiol 2005;95:915-18.
7. Somberg JC, Molnar J. Usefulness of QT dispersion as an electrocardiographically derived index. Am J Cardiol 2002;89:291-4.
8. Bazett HC. An analysis of the time-relation of electrocardiograms. Heart 1920;7:353-70.
9. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952;3:378-88.
10. Shah CP, Thakur RK, Reisdorff EJ, Lane E, Aufderheide TP, Hayes OW. QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center. Am Heart J 1998;136:496-8.
11. Glancy JM, Garratt CJ, de Bono DP. Dynamics of QT dispersion during myocardial infarction and ischaemia. Int J Cardiol 1996;57:55-60.
12. Yi G, Elliott P, McKenna WJ, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 1998;82:1514-19.
13. Zaidi M, Robert A, Fesler R, Derwael C, Brohet C. Dispersion of ventricular repolarization in hypertrophic cardiomyopathy. J Electrocardiol 1996;29(suppl):89-94.
14. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992;15:739-42.
15. Fei L, Goldman JH, Prasad K, et al. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J 1996;17:258-63.
16. Bonnar CE, Davie AP, Caruana L, et al. QT dispersion in patients with chronic heart failure: β-blockers are associated with a reduction in QT dispersion. Heart 1999;81:297-302.
17. Krantz MJ, Donahoo WT, Melanson EL, Mehler PS. QT interval dispersion and resting metabolic rate in chronic anorexia nervosa. Int J Eat Disord 2005;37:166-70.
18. Bonatti V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur Heart J 1983;4:168-79.
19. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval: a marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994;89:1681-9.
20. Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome. Br Heart J 1978;40:1014-18.
21. Garson A Jr. How to measure the QT interval: what is normal? Am J Cardiol 1993;72:14B-16.
22. Bednar MM, Harrigan EP, Ruskin JN. Torsade de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc. Am J Cardiol 2002;89:1316-19.
23. Kautzner J, Malik M. QT interval dispersion and its clinical utility. Pacing Clin Electrophysiol 1997;20:2625-40.
24. Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994;5:672-85.
25. Davey PP, Bateman J, Mulligan IP, Forfar C, Barlow C, Hart G. QT interval dispersion in chronic heart failure and left ventricular hypertrophy: relation to autonomic nervous system and Holter tape abnormalities. Br Heart J 1994;71:268-73.
26. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000;36:1749-66.
27. Surawicz B. Will QT dispersion play a role in clinical decision making? J Cardiovasc Electrophysiol 1996;8:777-84.
28. McFarlane PW, on behalf of the WOSCOPS. QT dispersion: lack of discriminating power [abstr]. Circulation 1998;98(suppl I):I-81.
29. Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26(4):852-8.
30. Cui G, Sen L, Sager P et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994;74(9):896-900.
31. Meierhenrich R, Helguera ME, Kidwell GA, Tebbe U. Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. Int J Cardiol 1997;60(3):289-94.
32. Grimm W, Steder U, Menz V, et al. Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events. Clin Cardiol 1997;20(2):107-10.
33. Pratt CM, Ruberg S, Morganroth J, et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 1996;131(3):472-80.
34. Iannini PB, Kubin R, Reiter C, et al. Reassuring safety profile of moxifloxacin [letter]. Clin Infect Dis 2001;32(7):1112-14.
35. Wang SH, Lin CY, Huang TY, et al. QT interval effects of cisapride in the clinical setting. Int J Cardiol 2001;80(2-3):179-83.
36. McBride BF, Karapanos AK, Krudysz A, et al. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial. JAMA 2004;291(2):216-21.
37. Zitron E, Schulz E, Owen RW, et al. QTc prolongation by grapefruit juice and its potential pharmacologic basis: HERG channel blockade by flavonoids. Circulation 2005;111:835-8.
38. Hartigan-Go K, Bateman DN, Nyberg G, et al. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans. Clin Pharmacol Ther 1996;60:543-53.
39. Oberg KC, Bauman JL. QT interval prolongation and torsade de pointes due to erythromycin lactobionate. Pharmacotherapy 1995;15:687-92.
40. Hu JT, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992;86(5):1376-82.
41. Trusz-Gluza M, Swiderska E, Smieja-Jaroczynska B, et al. Factors influencing dispersion of repolarisation under antiarrhythmic treatment [abstr]. Ann Noninvas Electrocardiol 1998;3:S18.
42. Faber TS, Zehender M, Krahnefeld O, et al. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 1997;29(3):561-7.
43. Dancey D, Wulffhart Z, McEwan P. Sotalol-induced torsade de pointes in patients with renal failure. Can J Cardiol 1997;13(1):55-8.
44. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone, Pain 2003;105(3):499-506.
45. Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol 2000;36(1):1-12.
46. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58(1):32-45.
47. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22.
48. Krantz MJ, Garcia JA, Mehler PS. Effects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005;25:611-14.